RNAZ ▲ +16.6% - TransCode Therapeutics, Inc. $RNAZ RNAZ - TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis TransCode Therapeutics shares rose 16.6% following the company's announcement of a publication showing that its experimental therapy TTX-MC138 demonstrated a survival benefit in a preclinical breast cancer bone metastasis model. The positive preclinical data appears to have bolstered investor confidence in the drug candidate's potential, driving the intraday gain. 31-AUG-2026 08:05 AM ET